RA
IPSC icon

Royce & Associates’s Century Therapeutics IPSC Stock Holding History

Royce & Associates’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-11,430
Closed -$58.6K – 931
2022
Q4 		$58.6K Buy
+11,430
New +$108K ﹤0.01% 899
2022
Q1 		– Sell
-12,900
Closed -$205K – 991
2021
Q4 		$205K Buy
+12,900
New +$242K ﹤0.01% 944

Other funds holding IPSC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royce & Associates's IPSC Position: Q1 2023 in Review

Royce & Associates sold out of Century Therapeutics (IPSC) in Q1 2023, closing a stake of 11,430 shares — an estimated $58.6K sold.

Royce & Associates first reported a position in IPSC in Q4 2021 and held it in 2 quarters. The position peaked at $205K in Q4 2021. 63 funds tracked by Wall St. Rank hold IPSC as of Q1 2023.

  • Royce & Associates reported no remaining Century Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Royce & Associates sold 11,430 Century Therapeutics shares in Q1 2023, an estimated $58.6K.
  • Royce & Associates first reported a position in Century Therapeutics in Q4 2021 and held it in 2 quarters.
  • Royce & Associates's Century Therapeutics position peaked at $205K in Q4 2021.
  • 63 funds tracked by Wall St. Rank held Century Therapeutics as of Q1 2023.

Based on Royce & Associates's 13F filing for Q1 2023, filed 4 May 2023.